Humacyte (HUMA) News Today $1.54 +0.05 (+3.36%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.54 0.00 (-0.06%) As of 04/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Shamik J. Parikh Acquires 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockApril 15 at 4:28 AM | insidertrades.comFranklin Resources Inc. Takes Position in Humacyte, Inc. (NASDAQ:HUMA)Franklin Resources Inc. acquired a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 433,482 shares of the company's stock, valued at approximately $2April 15 at 3:31 AM | marketbeat.comCenterBook Partners LP Makes New $6.46 Million Investment in Humacyte, Inc. (NASDAQ:HUMA)CenterBook Partners LP acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,279,839 shares of the company's stock, valued at approximately $6,463,000. CenterBook PApril 11, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Director Purchases $66,000.00 in StockHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) Director Kathleen Sebelius purchased 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.April 10, 2025 | marketbeat.comInsider Buying: Humacyte, Inc. (NASDAQ:HUMA) Director Acquires 50,000 Shares of StockApril 9, 2025 | insidertrades.comHumacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should KnowApril 3, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comHumacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma TreatmentMarch 31, 2025 | markets.businessinsider.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has isMarch 30, 2025 | marketbeat.comThrivent Financial for Lutherans Has $2.10 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)Thrivent Financial for Lutherans lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 217.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 415,262 shares of the company's stock after buying an additional 284,March 30, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPSHumacyte (NASDAQ:HUMA - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.08.March 29, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPSHumacyte (NASDAQ:HUMA - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.08.March 29, 2025 | marketbeat.comDurham biotech defends lead product after concerns surfaceMarch 28, 2025 | bizjournals.comHumacyte price target lowered to $8 from $10 at BTIGMarch 28, 2025 | markets.businessinsider.comHumacyte down following quarterly results, hits record lowMarch 28, 2025 | msn.comHumacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More BullishMarch 28, 2025 | msn.comHumacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call TranscriptMarch 28, 2025 | seekingalpha.comHumacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business UpdateMarch 28, 2025 | globenewswire.comHumacyte CEO addresses concerns in NYT over FDA approval of SymvessMarch 27, 2025 | investing.comDurham biotech's stock price drops 30% amid offering, reports about product safetyMarch 27, 2025 | bizjournals.comHumacyte Defends Symvess Approval Amid FDA ScrutinyMarch 27, 2025 | tipranks.comD. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Wednesday.March 27, 2025 | marketbeat.comHumacyte capital raise brings buying opportunity, says D. Boral CapitalMarch 27, 2025 | markets.businessinsider.comHumacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To DispelMarch 27, 2025 | seekingalpha.comHumacyte stock plunges on public offering pricingMarch 26, 2025 | au.investing.comHumacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025March 26, 2025 | globenewswire.comHumacyte 25M share Spot Secondary priced at $2.00March 26, 2025 | markets.businessinsider.comHumacyte stock slides on pricing public offering of units to raise $50MMarch 26, 2025 | msn.comHumacyte (HUMA) Projected to Post Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.March 26, 2025 | marketbeat.comHumacyte, Inc. Announces Pricing of Public Offering of Common StockMarch 25, 2025 | globenewswire.comUS Approved Device for Battlefield Injuries Despite Serious Risks, Former FDA Reviewer SaysMarch 25, 2025 | msn.comHumacyte down 13% amid reports that FDA approved device despite warningsMarch 25, 2025 | msn.comHumacyte's Stock Drops Below 52-Week Low Amidst Share SaleMarch 25, 2025 | marketwatch.comHumacyte, Inc. Announces Proposed Public Offering of Common StockMarch 25, 2025 | globenewswire.comF.D.A. Approved Lab-Grown Blood Vessel DespiteWarningsMarch 24, 2025 | nytimes.comHumacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)March 24, 2025 | seekingalpha.comHumacyte (HUMA) to Release Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.March 21, 2025 | marketbeat.comHumacyte's (HUMA) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research report on Wednesday.March 13, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyMarch 12, 2025 | msn.comHumacyte announces publication of Budget Impact Model for SymvessMarch 10, 2025 | markets.businessinsider.comHumacyte price target lowered to $7.50 from $10 at TD CowenMarch 10, 2025 | markets.businessinsider.comHumacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical EconomicsMarch 10, 2025 | globenewswire.comTrestle Bio Unveils Research Partnership With HumacyteMarch 8, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Friday.March 8, 2025 | marketbeat.comTrestle Bio Announces Research Collaboration with HumacyteMarch 6, 2025 | finance.yahoo.comHumacyte, Trestle Biotherapeutics announce research collaborationMarch 6, 2025 | markets.businessinsider.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from BrokeragesHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received an average recommendation of "Buy" from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a stronMarch 4, 2025 | marketbeat.comHumacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025March 3, 2025 | globenewswire.comHumacyte's (HUMA) "Buy" Rating Reiterated at BenchmarkBenchmark reaffirmed a "buy" rating on shares of Humacyte in a research report on Thursday.February 28, 2025 | marketbeat.comHumacyte to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.com Remove Ads Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼1.660.78▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼910▲HUMA Articles Average Week Remove Ads Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COLL News Today DYN News Today ELVN News Today RCUS News Today CMRX News Today CDMO News Today SYRE News Today NTLA News Today ZYME News Today VIR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
